Indianapolis-based Eli Lilly and Co. (NYSE: LLY) Tuesday morning announced a $90 million investment designed to give greater access to health care for 30 million underserved people globally by 2030. Lilly 30×30 will focus on widening the availability of diabetes, cancer and tuberculosis treatments. Chief Executive Officer John Lechleiter says the Lilly Global Health Partnership initiative is a company-wide mandate to increase the number of people reached each year outside the traditional business by six times.
During a Tuesday morning presentation at the Lilly Corporate Center, Lechleiter said the company and the Eli Lilly and Co. Foundation will tap into a range of resources. He says the initiative can tap into "not only our financial resources, but also our capabilities as a company and the expertise and dedication of Lilly people. Working side-by-side with our partners, we seek to be a catalyst for ideas, solutions, action and most importantly, results."
Lilly 30×30 will be funded half by the company and half by the Eli Lilly and Co. Foundation. It adds cancer as a new therapeutic area of focus for the Global Partnership, identifying new opportunities in countries including Brazil, China, India, Kenya, Mexico, Russia, South Africa and the U.S. Those involved will work toward finding new care models, research report findings and push to scale-up the most-effective solutions, including $15 million allocated for the Infectious Disease Research Institute, extending an eight-year collaboration aimed at finding new TB medicines.
You can connect to more about the initiative by clicking here.